Two-drug therapy for B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tests two targeted drugs, inotuzumab and blinatumomab, for people with B-cell acute lymphoblastic leukemia (ALL). The goal is to see if this combination can help control the cancer and possibly be an option for those who cannot have standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have B-cell acute lymphoblastic leukemia (ALL) that is newly diagnosed or has come back after treatment.
- If newly diagnosed, you must be 55 or older, or between 18 and 54 and not able to have standard chemotherapy due to health issues.
- Your leukemia cells must have certain markers (CD19 and CD22) on them.
- You must not have a specific genetic change called the Philadelphia chromosome.
- Your liver, kidneys, and heart must be working well enough (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a combination of two treatments—blinatumomab and a special type of immune cell called iNKT—to fight B-cell acute lymphoblastic leukemia (ALL) that has returned or is not responding well after prior treatment. The goal is to see if this combination is safe and effective for patients who have had a relapse or new minimal residual disease (MRD) after previous treatment.
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.